Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

OpGen Inc (OPGN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow OpGen's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.582 -0.018    -2.98%
13:32:30 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 156,403
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.565 - 0.610
OpGen 0.582 -0.018 -2.98%

OPGN Analyst Price Target

 
Our OpGen Inc stock forecast data is based on consensus analyst prediction, covering public companies earnings per share and revenue. Assess the OpGen stock price estimates. View analyst opinion as to whether the stock is a strong buy, strong sell or hold, based on analyst 12-Month OPGN price targets.
No data available

Technical Analysis

Summary:Strong Sell
Moving Averages:Strong SellBuy (0)Sell (12)
Technical Indicators:Strong SellBuy (1)Sell (9)

Recent Sentiments

BearishBullish
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

OPGN Comments

Write your thoughts about OpGen Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Jack Belforte
Jack Belforte Dec 13, 2022 7:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Time for a dollar play.
Financial Advisors
Financial Advisors Jan 01, 2022 11:53PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
run run sell out , i love 60k with Curetis when they tie up merger with OpGen ...pity , i advise as a friend to friend sell out before to be late.
Dec 16, 2021 8:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
We’ll be surprised that one morning this stock will fly to the moon.🥂
Dec 16, 2021 7:59PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Following successful completion of Phase 1, Ares Genetics has now entered into Phase 2 of its collaboration with a leading U.S. CRO and reference lab, gaining access to 1,000 proprietary clinical isolates from key pathogensARESdb contents has grown by more than 40% in a yearROCKVILLE, Md., Dec. 14, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that its subsidiary, Ares Genetics (Ares), has successfully completed Phase 1 of its collaboration with a leading U.S. CRO and reference lab, originally announced in August. During Phase 2, Ares will gain access to 1,000 proprietary genome and AST datasets thereby strategically enriching ARESdb with proprietary data for key pathogens.Antimicrobial resistance (AMR) is a growing threat to public health believed to be causing 700,000 fatalities globally each year and bill
Mohammed Aloraini
Mohammed Aloraini Oct 18, 2021 12:20PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
to the moon
Oct 18, 2021 11:34AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This is worse than pump and dump. I will in if this will reach at 0.99/share
Jonathan McBrine
Jonathan McBrine Oct 14, 2021 6:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
can anyone tell me why this is abl buy
Tommi Nuutinen
Tommi Nuutinen Oct 11, 2021 2:22AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hodling with diamonds.
Oct 08, 2021 6:06PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Yeah they want us to sell so when the price is dip those manipulators will buy.. So, I would say, let them down the price, don’t buy for now. Just wait, if they want it at the very low price then let it be. Don’t buy and don’t sell either. 💪💪
Pupi Pi
Pupi Pi Oct 06, 2021 10:44AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Manipulation by short hedge funds. No worries.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email